Extracellular Vesicle-Encapsulated Adeno-Associated Viruses for Therapeutic Gene Delivery to the Heart
2024

Gene therapy for the heart: encapsulated viruses to the rescue

Commentary Evidence: moderate

Author Information

Author(s): Deshetty Uma Maheswari, Sil Susmita, Buch Shilpa

Primary Institution: University of Nebraska Medical Center

Conclusion

The study demonstrates that extracellular vesicle-encapsulated adeno-associated viruses can effectively deliver therapeutic genes to the heart, improving cardiac function despite the presence of neutralizing antibodies.

Supporting Evidence

  • Extracellular vesicles can shuttle bioactive cargoes to recipient cells.
  • EV-AAVs showed increased gene delivery efficacy to ischemic hearts.
  • The study validated the therapeutic potential of EV-AAVs in murine hearts.

Takeaway

This study shows that tiny bubbles from cells can help deliver medicine to the heart better than regular methods, even when the body tries to fight the medicine.

Methodology

The study involved optimizing the purification of extracellular vesicle-encapsulated adeno-associated viruses and validating their efficacy in various in vitro and in vivo models.

Limitations

The study may have off-target effects, particularly delivery to organs like the liver, and lacks discussion on the specificity of the EVs for cardiomyocytes.

Digital Object Identifier (DOI)

10.20517/evcna.2023.70

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication